4554
Fiscal year ends September Quarters are offset from the calendar — Q1 is Oct–Dec

Fuji Pharma Co., Ltd. is a pharmaceutical company focused on the development, manufacturing, and sales of injectable medications. The company operates a single business segment comprising therapeutic and diagnostic drugs. Its product portfolio is centered on hormonal agents for obstetrics and gynecology and contrast media for radiology, specifically for urinary and vascular imaging. Fuji Pharma serves the Japanese market through a network of five offices and maintains a subsidiary relationship with OLIC (Thailand) Limited for product trading and financial transactions. The company is currently developing new indications and dosage forms for existing hormonal agents, sustained-release formulations, and biogeneric drugs utilizing recombinant technology.

Summarised from the annual report, fiscal year ended Sep 2025

Industry Drug Manufacturers - Specialty & Generic Homepage fujipharma.jp
Sector Healthcare IR page fujipharma.jp
Tags
hormonal agents, contrast media, obstetrics, gynecology, radiology, biogenerics, sustained-release formulations, injectable medications, OLIC (Thailand) Limited
Press page fujipharma.jp/news

Metrics

Valuation  
Market cap ¥ 46.845B
Market cap (USD) $ 292.785M
P/E 15.88
PEG —
P/BV 0.89
P/S 0.75
P/OCF 7.59
P/FCF 24.06
Dividend yield 2.9%
Turnover / mcap —
Returns  
ROE 5.7%
ROI 5.4%
ROIC 9.1%
Profit margin 4.5%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -6.2%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 11
Quality score 22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 62.386B 51.677B 46.138B 40.889B 35.426B 33.99B 33.793B 36.279B 37.909B 35.387B 34.229B 31.68B 29.215B 25.174B 21.52B
Net profit 2.831B 3B 6.146B 3.435B 2.696B 2.432B 2.085B 2.962B 3.372B 3.301B 2.118B 2.092B 2.078B 2.068B 1.37B
Free cash flow — 1.947B -221M -1.98B -13.081B 2.097B 3.155B 3.751B 2.143B 1.696B 1.855B -954M — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 1.765K 1.546K 1.273K 1.166K 1.034K 1.17K 1.249K 1.317K 1.792K 3.839K 2.681K 2.002K 2.031K 1.737K 1.286K
Price performance 12m 0.14 0.21 0.09 0.13 -0.12 -0.06 -0.05 -0.26 -0.53 0.43 0.34 -0.01 0.17 0.35 —

Filed figures

Figure Sep 2017 Sep 2018 Sep 2019 Sep 2020 Sep 2021 Sep 2022 Sep 2023 Sep 2024 Sep 2025 Sep 2026
Balance sheet detail
Trade receivables (JPY) 15.1B 16.9B 12.9B 11.7B 11.9B 12.5B 16.3B 18.4B 18B 20.5B
↳ YoY growth +15.8% +11.6% -23.4% -9.6% +1.4% +5.6% +30.2% +13.0% -2.4% +14.1%
↳ 5y CAGR -1.1% -1.9% -3.7% -0.7% +7.3% +9.0% +11.6%
Other receivables (JPY) 20M 39M 43M 8M 118M 134M 216M 453M 296M 454M
Borrowings, current (JPY) 653M — 2.84B 2.64B 8.84B 10.7B 16.5B 22.4B 17.3B 17.2B
Borrowings, non-current (JPY) 2B 2B 5.53B 7.59B 6.63B 11.2B 8.68B 1.58B 8.95B 7.05B
Bonds payable (JPY) — — — — — — 2.7B 2.1B 2.45B 1.75B
Lease liabilities (JPY) 2.21B 3.07B 2.54B 1.96B 3.19B 2.64B 3.76B 5.27B 4.7B 4.12B
Cash and deposits (JPY) 5.5B 6.25B 8.49B 12B 10.2B 3.55B 2.32B 4.59B 7.25B 9.5B
Intangible assets (JPY) 2.71B 2.22B 3.3B 2.9B 2.4B 10.4B 10.5B 12.4B 13.9B 13.7B
Net debt (borrowings + leases - cash) (JPY) -638M -1.18B 2.42B 149M 8.46B 21B 26.6B 24.7B 23.7B 18.9B
Cash flow detail
Operating cash flow (JPY) 3.24B 3.77B 7.04B 5.77B 5.99B -658M 1.92B 4.15B 5.8B 6.17B
Purchases of property, plant and equipment (JPY) -1.48B -1.45B -1.7B -2.32B -3.79B -5.1B -3.33B -2.78B -1.98B -2.09B
Purchases of intangible assets (JPY) -65M -184M -1.58B -293M -107M -7.33B -570M -1.59B -1.87B -1.81B
Change in receivables (cash effect) (JPY) -1.98B -1.73B 3.97B 1.2B -174M -549M -3.71B -2B 525M -2.53B
Change in inventories (cash effect) (JPY) 185M 235M 581M -23M -1.34B -3.62B -3.4B 1.55B -3.08B -1.29B
Change in payables (cash effect) (JPY) -642M 994M -1.94B -1.1B 2.04B 447M -652M -1.64B 356M -895M
Dividends paid (cash effect) (JPY) -704M -794M -839M -904M -807M -729M -899M -972M -1.04B -1.23B
Share buybacks (cash effect) (JPY) 0.00 -40M 0.00 0.00 -9.41B — — — — —
Interest paid (cash effect) (JPY) -45M -70M -53M -41M -59M -82M -104M -194M -327M -393M
Income taxes paid (cash effect) (JPY) -1.09B -1.8B -957M -723M -911M -1.5B -946M -1.03B -2.2B -1.76B
Operating cash flow before change in receivables (JPY) 5.22B 5.5B 3.07B 4.57B 6.17B -109M 5.62B 6.15B 5.28B 8.7B
Free cash flow (OCF - PPE - intangibles) (JPY) 1.7B 2.14B 3.75B 3.16B 2.1B -13.1B -1.98B -221M 1.95B 2.28B
Income detail
Research and development expense (JPY) 1.83B 1.76B 2.05B 3.06B 2.45B 2.49B 3.18B 3.4B 3.34B 4.06B
↳ 5y CAGR +12.1% +5.9% +6.4% +12.6% +10.6% +1.8% +10.7%
Total comprehensive income (JPY) 4.07B 3.57B 2.61B 1.49B 2.9B 3.89B 6.26B 5.29B 2.17B 3.45B
Comprehensive income to owners (JPY) 4.07B 3.57B 2.61B 1.49B 2.9B 3.89B 6.26B 5.29B 2.17B 3.45B
Reported Dec 20, 2017 Dec 19, 2018 Dec 19, 2019 Dec 18, 2020 Dec 20, 2021 Dec 21, 2022 Dec 21, 2023 Dec 23, 2024 Dec 18, 2025 Nov 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

2026年9月期決算補足資料 Bull 3 Bear 0 Results
剰余金の配当(増配)に関するお知らせ Bull 3 Bear 0 Capital return

Prompts

Fuji Pharma Co., Ltd. (ticker 4554), listed in Japan.

ETFs Holding Fuji Pharma Co., Ltd.

ETF Weight in ETF Shares Market value As of
DISV 0.03% 131,499 $ 1.544M Nov 12, 2026
AVDV 0.02% 251,700 $ 2.932M Nov 16, 2026
AVDS 0.01% 2,300 $ 26.795K Nov 16, 2026
DXIV 0.01% 1,800 $ 21.141K Nov 12, 2026
DFIS 0.01% 32,400 $ 380.533K Nov 12, 2026
DFIC 0.00% 29,000 $ 340.6K Nov 12, 2026
DFAX 0.00% 16,700 $ 196.139K Nov 12, 2026
DFAI 0.00% 21,100 $ 247.816K Nov 12, 2026
AVDE 0.00% 20,500 $ 238.826K Nov 16, 2026